{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:49:46Z","timestamp":1769921386178,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05461-6","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T04:01:30Z","timestamp":1696478490000},"page":"175-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-6807","authenticated-orcid":false,"given":"Fernanda Maria","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Flavio Gomes","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Santos","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wellington Fernandes","family":"Silva-Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Bassolli O.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederico R.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Dolphini","family":"Velasques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Junqueira","family":"Atanazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina Arrais","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Buchpiguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Buccheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"5461_CR1","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: An analysis of international staging definitions. Ann Oncol 24:3070\u20133076. https:\/\/doi.org\/10.1093\/annonc\/mdt413","journal-title":"Ann Oncol"},{"key":"5461_CR2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin\u2019s disease. N Engl J Med 339:1506\u20131514","journal-title":"N Engl J Med"},{"key":"5461_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372:1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"key":"5461_CR4","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPEE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPEE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35:1786\u20131796. https:\/\/doi.org\/10.1200\/JCO.2016.68.6394","journal-title":"J Clin Oncol"},{"key":"5461_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hon.2437","volume":"35","author":"J Trotman","year":"2017","unstructured":"Trotman J, Fossa A, Federico M et al (2017) Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: Longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK\/07\/033). Hematol Oncol 35:65\u201367. https:\/\/doi.org\/10.1002\/hon.2437","journal-title":"Hematol Oncol"},{"key":"5461_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/hon.2227","volume":"33","author":"PW Johnson","year":"2015","unstructured":"Johnson PW, Federico M, Fossa A et al (2015) Response-adapted therapy based on interim FDG-PET scans in advanced hodgkin lymphoma: First analysis of the safety of de-escalation and efficacy of escalation in the international rathl study (cruk\/07\/033). Hematol Oncol 33:102\u2013103. https:\/\/doi.org\/10.1002\/hon.2227","journal-title":"Hematol Oncol"},{"key":"5461_CR7","first-page":"145","volume":"102","author":"A Gallamini","year":"2017","unstructured":"Gallamini A, Rossi A, Patti K et al (2017) Early chemotherapy intensification with escalated BEACOPP in advanced-stage Hodgkin lymphoma with a positive interim PET-CT after 2 ABVD cycles: Long-term results of the GITIL\/FIL HD 0607 trial. Haematologica 102:145\u2013146","journal-title":"Haematologica"},{"key":"5461_CR8","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746\u20133752. https:\/\/doi.org\/10.1200\/JCO.2007.11.6525","journal-title":"J Clin Oncol"},{"key":"5461_CR9","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","volume":"34","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Broccoli A, Gioia DM et al (2016) Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study. J Clin Oncol 34:1376\u20131385. https:\/\/doi.org\/10.1200\/JCO.2015.63.0699","journal-title":"J Clin Oncol"},{"key":"5461_CR10","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374:2419\u20132429. https:\/\/doi.org\/10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"key":"5461_CR11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1182\/blood.2019000719","volume":"134","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Li H, Schoder H et al (2019) Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma. Blood 134:1238\u20131246. https:\/\/doi.org\/10.1182\/blood.2019000719","journal-title":"Blood"},{"key":"5461_CR12","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","volume":"51","author":"JJ Cerci","year":"2010","unstructured":"Cerci JJ, Pracchia LF, Linardi CCG et al (2010) 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51:1337\u20131343. https:\/\/doi.org\/10.2967\/jnumed.109.073197","journal-title":"J Nucl Med"},{"key":"5461_CR13","doi-asserted-by":"publisher","unstructured":"Straus DJ, Dlugosz-Danecka M, Alekseev S, et al (2019) Brentuximab vedotin with chemotherapy for stage 3\/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study. J Clin Oncol 37:. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.7532","DOI":"10.1200\/JCO.2019.37.15_suppl.7532"},{"key":"5461_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/hon.2437","volume":"35","author":"AS Cottereau","year":"2017","unstructured":"Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Cottereau A, Versari A et al (2017) Prognostic value of baseline total metabolic tumor volume (TMTV) for patients with early stage Hodgkin lymphoma enrolled in the standard arm of the H10 (EORTC\/LYSA\/FIL) trial. Hematol Oncol 35:35\u201336. https:\/\/doi.org\/10.1002\/hon.2437","journal-title":"Hematol Oncol"},{"key":"5461_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2967\/jnumed.118.210047","volume":"60","author":"J Mettler","year":"2019","unstructured":"Mettler J, M\u00fcller H, Voltin CA et al (2019) Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med 60:207\u2013211. https:\/\/doi.org\/10.2967\/jnumed.118.210047","journal-title":"J Nucl Med"},{"key":"5461_CR16","doi-asserted-by":"publisher","unstructured":"Pinochet P, Texte E, Stamatoullas-Bastard A, et al (2021) Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin\u2019s lymphoma. Sci Rep 11:. https:\/\/doi.org\/10.1038\/s41598-021-02734-w","DOI":"10.1038\/s41598-021-02734-w"},{"key":"5461_CR17","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00277-020-04039-w","volume":"99","author":"D Albano","year":"2020","unstructured":"Albano D, Mazzoletti A, Spallino M et al (2020) Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. Ann Hematol 99:1321\u20131330. https:\/\/doi.org\/10.1007\/s00277-020-04039-w","journal-title":"Ann Hematol"},{"key":"5461_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington SF, Meignan M (2019) Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med 60:1096\u20131102. https:\/\/doi.org\/10.2967\/jnumed.119.227249","journal-title":"J Nucl Med"},{"key":"5461_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/blood.v128.22.184.184","volume":"128","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Versari A, Loft A et al (2016) Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC\/Lysa\/FIL H10 Trial. Blood 128:184\u2013184. https:\/\/doi.org\/10.1182\/blood.v128.22.184.184","journal-title":"Blood"},{"key":"5461_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2967\/jnumed.113.130609","volume":"55","author":"C Rossi","year":"2014","unstructured":"Rossi C, Kanoun S, Berriolo-Riedinger A et al (2014) Interim 18f-FDG PET Suvmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med 55:569\u2013573. https:\/\/doi.org\/10.2967\/jnumed.113.130609","journal-title":"J Nucl Med"},{"key":"5461_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","volume":"36","author":"G Bonadonna","year":"1975","unstructured":"Bonadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252\u2013259. https:\/\/doi.org\/10.1002\/1097-0142(197507)36:1%3c252::AID-CNCR2820360128%3e3.0.CO;2-7","journal-title":"Cancer"},{"key":"5461_CR22","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"5461_CR23","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N Engl J Med 363:640\u2013652. https:\/\/doi.org\/10.1056\/NEJMoa1000067","journal-title":"N Engl J Med"},{"key":"5461_CR24","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048\u20133058. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229","journal-title":"J Clin Oncol"},{"key":"5461_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2014","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG et al (2014) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5461_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","volume":"30","author":"C Contal","year":"1999","unstructured":"Contal C, O\u2019Quigley J (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30:253\u2013270. https:\/\/doi.org\/10.1016\/S0167-9473(98)00096-6","journal-title":"Comput Stat Data Anal"},{"key":"5461_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0562-7","volume-title":"Statistical tools for measuring agreement","author":"LH Lin","year":"2012","unstructured":"Lin LH, Hedayat A, Wu W (2012) Statistical tools for measuring agreement. Springer"},{"key":"5461_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hon.2450","volume":"36","author":"I Biasoli","year":"2018","unstructured":"Biasoli I, Castro N, Delamain M et al (2018) Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. Hematol Oncol 36:189\u2013195. https:\/\/doi.org\/10.1002\/hon.2450","journal-title":"Hematol Oncol"},{"key":"5461_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s44228-022-00008-4","volume":"4","author":"C Mahuad","year":"2022","unstructured":"Mahuad C, Victoria O, Laura K, Enriqueta M, Fernando W, Hern\u00e1n GR et al (2022) Retrospective multicenter real-life study on the first-line treatment of classical Hodgkin lymphoma in Argentina. Clin Hematol Int 4:44\u201351. https:\/\/doi.org\/10.1007\/s44228-022-00008-4","journal-title":"Clin Hematol Int"},{"key":"5461_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.21320\/2500-2139-2017-10-2-182-186","volume":"10","author":"AA Rukavitsyn","year":"2017","unstructured":"Rukavitsyn AA, Kurbanov SI, Rukavitsyn OA (2017) Prognostic and Differential Diagnostic Value of Standardized Uptake Volume (SUV) of Fluorodeoxyglucose in Patients with Hodgkin\u2019s Lymphoma. Clin Oncohematol 10:182\u2013186. https:\/\/doi.org\/10.21320\/2500-2139-2017-10-2-182-186","journal-title":"Clin Oncohematol"},{"key":"5461_CR31","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.21873\/anticanres.12011","volume":"37","author":"MK Angelopoulou","year":"2017","unstructured":"Angelopoulou MK, Mosa E, Pangalis GA et al (2017) The significance of PET\/CT in the initial staging of hodgkin lymphoma: Experience outside clinical trials. Anticancer Res 37:5727\u20135736. https:\/\/doi.org\/10.21873\/anticanres.12011","journal-title":"Anticancer Res"},{"key":"5461_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","volume":"131","author":"M Akhtari","year":"2018","unstructured":"Akhtari M, Milgrom SA, Pinnix CC et al (2018) Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood 131:84\u201394. https:\/\/doi.org\/10.1182\/blood-2017-04-773838","journal-title":"Blood"},{"key":"5461_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-7-5","volume":"7","author":"D Tseng","year":"2012","unstructured":"Tseng D, Rachakonda L, Su Z, Advani R, Horning SHR et al (2012) Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin\u2019s disease Tseng D. Radiat Oncol 7:1\u20137","journal-title":"Radiat Oncol"},{"key":"5461_CR34","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A et al (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41:1735\u20131743. https:\/\/doi.org\/10.1007\/s00259-014-2783-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5461_CR35","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2016.34.15_suppl.7509","volume":"34","author":"RO Casasnovas","year":"2016","unstructured":"Casasnovas RO, Kanoun S, Tal I, Cottereau AS, Edeline V, Brice P et al (2016) Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial. J Clin Oncol 34:7509. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.7509","journal-title":"J Clin Oncol"},{"key":"5461_CR36","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/cas.12282","volume":"104","author":"MK Song","year":"2013","unstructured":"Song MK, Chung JS, Lee JJ et al (2013) Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin\u2019s lymphoma. Cancer Sci 104:1656\u20131661. https:\/\/doi.org\/10.1111\/cas.12282","journal-title":"Cancer Sci"},{"key":"5461_CR37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.23994","volume":"90","author":"L Rigacci","year":"2015","unstructured":"Rigacci L, Puccini B, Zinzani PL et al (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90:499\u2013503. https:\/\/doi.org\/10.1002\/ajh.23994","journal-title":"Am J Hematol"},{"key":"5461_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-137089","volume":"136","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, Dlugosz-Danecka M, Connors JM et al (2020) Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III\/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Blood 136:26\u201328. https:\/\/doi.org\/10.1182\/blood-2020-137089","journal-title":"Blood"},{"key":"5461_CR39","doi-asserted-by":"publisher","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17\\_suppl.LBA4","volume":"41","author":"AF Herrera","year":"2023","unstructured":"Herrera AF, LeBlanc ML, Castellino SM et al (2023) SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol 41:LBA4\u2013LBA4. https:\/\/doi.org\/10.1200\/JCO.2023.41.17\\_suppl.LBA4","journal-title":"J Clin Oncol"},{"key":"5461_CR40","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","volume":"16","author":"M Hutchings","year":"2005","unstructured":"Hutchings M, Mikhaeel NG, Fields PA et al (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160\u20131168. https:\/\/doi.org\/10.1093\/annonc\/mdi200","journal-title":"Ann Oncol"},{"key":"5461_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","volume":"39","author":"PL Zinzani","year":"2012","unstructured":"Zinzani PL, Rigacci L, Stefoni V et al (2012) Early interim 18F-FDG PET in Hodgkin\u2019s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 39:4\u201312. https:\/\/doi.org\/10.1007\/s00259-011-1916-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5461_CR42","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","volume":"99","author":"AA Gallamini","year":"2014","unstructured":"Gallamini AA, Barrington SF, Biggi A et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99:1107\u20131113. https:\/\/doi.org\/10.3324\/haematol.2013.103218","journal-title":"Haematologica"},{"key":"5461_CR43","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers15061760","volume":"15","author":"S Zheng","year":"2023","unstructured":"Zheng S, Gupta K, Goyal P et al (2023) Outcomes of patients with positive pnterim Positron Emission Tomography (PET) continuing ABVD in the clinical setting. Cancers (Basel) 15:1760. https:\/\/doi.org\/10.3390\/cancers15061760","journal-title":"Cancers (Basel)"},{"key":"5461_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00277-019-03892-8","volume":"99","author":"S Yang","year":"2020","unstructured":"Yang S, Qiu L, Huang X et al (2020) The prognostic significance of \u0394SUVmax assessed by PET\/CT scan after 2 cycles of chemotherapy in patients with classic Hodgkin\u2019s lymphoma. Ann Hematol 99:293\u2013299. https:\/\/doi.org\/10.1007\/s00277-019-03892-8","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05461-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:03:40Z","timestamp":1704218620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05461-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5461"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05461-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"21 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Faculdade de Medicina of the Universidade de Sao Paulo in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (number: 79442717.0.0000.0065\u2014CAAE- Plataforma Brasil).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical appproval"}},{"value":"No authors have conflicts of interest or funding to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}